Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women

American Journal of Obstetrics and Gynecology

Volumn 207, Issue 1, 2012, Pages 59.e1-59.e7

  Zheteyeva, Yenlik A ^a,b   Moro, Pedro L ^a   Tepper, Naomi K ^c   Rasmussen, Sonja A ^d   Barash, Faith E ^f   Revzina, Natalia V ^e   Kissin, Dmitry ^c   Lewis, Paige W ^a   Yue, Xin ^a   Haber, Penina ^a   Tokars, Jerome I ^a   Vellozzi, Claudia ^a   Broder, Karen R ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^d NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

acellular pertussis vaccine; adverse events; epidemiology; pregnancy; reduced diphtheria toxoid; surveillance; tetanus toxoid; vaccine safety

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BODY RASH; CESAREAN SECTION; DRUG SURVEILLANCE PROGRAM; FEMALE; FEVER; GASTROSCHISIS; HEADACHE; HUMAN; HYDROCELE; INFLUENZA; INJECTION SITE REACTION; JAUNDICE; LABOR INDUCTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; OLIGOHYDRAMNIOS; OUTCOME ASSESSMENT; PATENT FORAMEN OVALE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; SYNCOPE; TACHYPNEA; THROMBOPHLEBITIS; TOXEMIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84862688726     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2012.05.006     Document Type: Article

References (32)

1. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011;204:334.e1-5.
2. Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a pre-pregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011;30:608-10.
3. Healy CM, Rench MA, Baker CJ. Implementation of cocooning against pertussis in a highrisk population. Clin Infect Dis 2011;52:157-62.
4. Cortese MM, Baughman AL, Zhang R, Srivastava PU, Wallace GS. Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics 2008;121:484-92.
5. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, March 15, 2005: FDA Adacel briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4097B1- 4a.pdf. Accessed Feb. 2, 2012.
6. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, March 15, 2005: FDA Boostrix briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4097B1-1.pdf. Accessed Feb. 2, 2012.
7. Murphy TV, Slade BA, Broder KR, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-51.
8. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1424-6.
9. US Department of Health and Human Services. Vaccine Adverse Event Reporting System (VAERS). Available at: http://www.vaers.hhs.gov/index. Accessed Feb. 2, 2012.
10. Varricchio F, Iskander J, DeStefano F. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004;23:287-94.
11. Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994;12:542-50.
12. US Department of Health and Human Services. Vaccine Adverse Event Reporting System form. Available at: http://www.vaers.hhs-.gov/resources/vaers- form.pdf. Accessed Feb. 2, 2012.
13. Northrop Grumman Corporation. Medical Dictionary for Regulatory Activities maintenance and support services organization; 2010. Available at: http://www.meddramsso.com/index.asp. Accessed Feb. 2, 2012.
14. US Food and Drug Administration. 21 Code of Federal Regulation Part 600.80. Postmarketing reporting of adverse experiences. Fed Regist 1997;62:52252-3. Available at: http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=600.80. Accessed Feb. 2, 2012.
15. Prenatal care. In: Cunningham G, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, Wenstrom KD, eds. Williams obstetrics. New York: McGraw-Hill Companies, Inc; 2001:221-47.
16. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10:483-6.
17. Banks D, Woo EJ, Burwen DR, Perucci P, BraunMM,Ball R. Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf 2005;14:601-9.
18. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol 2011;204:146.e1-7.
19. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events in pregnant women following administration of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System (VAERS). Am J Obstet Gynecol 2011;205:473.e1-9.
20. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-48.
21. Wright JG, Quinn CP, Shadomy S, Messonnier N; Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010;59:1-30.
22. Moore TR, Cayle JE. The amniotic fluid index in normal human pregnancy. Am J Obstet Gynecol 1990;162:1168-73.
23. Wang M, Khromava A, Mahmood A, Dickinson N. Pregnant women receiving tetanus-diphtheria-acellular pertussis (Tdap) vaccine: 6 years of Adacel vaccine pregnancy registry data. Presented at the 27th International Conference on Pharmacoepidemiology and Therapeutic Management, Chicago, IL. Pharmacoepidemiol Drug Saf 2011;20:S1-364.
24. Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22.
25. Canfield MA, Honein MA, Yuskiv N, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 2006;76:747-56.
26. Rasmussen SA, Frias JL. Non-genetic risk factors for gastroschisis. Am J Med Genet C Semin Med Genet 2008;148C:199-212.
27. Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the Vaccine Adverse Event Reporting System. Vaccine 2012;30:2020-3.
28. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; on behalf of the VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012;30:2024-31.
29. US Department of Health and Human Services. Charter of Advisory Committee on Immunization Practices, April 1, 2010. Available at: http://www.cdc.gov/ vaccines/recs/acip/downloads/charter.pdf. Accessed Feb. 2, 2012.
30. Czeizel AE, Rockenbauer M. Tetanus toxoid and congenital abnormalities. Int J Gynecol Obstet 1999;64:253-8.
31. Silveria CM, Caceres VM, Dutra MG, Lopes-Camelo J, Castilla EE. Safety of tetanus toxoid in pregnant women: a hospital-based case-control study of congenital anomalies. Bull World Health Organ 1995;73:605-8.
32. Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KR. The safety of immunizing with tetanus- diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010;20:8001-7.